Details | Patients (%) | |
---|---|---|
Age | Median (range), years | 72 (53–91) |
Time between ADT and ARTT | Median (range), months | 48.1 (12.1–123.3) |
RT techniques | 3DRT | 24 (82.7%) |
SBRT | 5 (17.3%) | |
ARTT | Abiraterone | 21 (72.4%) |
Enzalutamide | 8 (27.6%) | |
Treatment line | I | 17 (58.6%) |
II-III | 12 (41.4%) | |
PSA after 1 month from the start of ARTT | Median (range), ng/ml | 3.02 (0.02–100) |
≤50% reduction | 5 (17.2%) | |
> 50% reduction | 24 (82.8%) | |
RT timing respect the start of ARTT | < 6 months | 15 (51.7%) |
> 6 months | 14 (48.3%) | |
RT sites | Lesions (%) | |
Bones | 31 (83%) | |
Lung | 2 (5.5%) | |
Lymphnodes | 2 (5.5%) | |
Prostatic Bed | 2 (5.5%) |